Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

Completed · Phase 3

Conditions studied: Congenital Bleeding Disorder, Haemophilia B

In brief

This trial is conducted in Africa, Asia, Europe, Japan and North America. The aim of this trial is to evaluate the safety and efficacy, including pharmacokinetics (the rate at which the body eliminates the trial drug), of NNC-0156-0000-0009 (nonacog beta pegol) when used for treatment and prophylaxis of bleeding episodes in patients with haemophilia B.

Key facts

Study ID

NCT01333111

Run by

Novo Nordisk A/S

People needed

74

Starts

2011-04-27

Expected to finish

2013-03-31

Last updated by the study team

2017-07-28

Who can join

Age: 13 and older, up to 70. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male patients with moderately severe or severe congenital haemophilia B with a factor IX activity of 2% or below according to medical records
• History of at least 150 exposure days to other factor IX products
• Patients currently treated on-demand with at least 6 bleeding episodes during the last 12 months or at least 3 bleeding episodes during the last 6 months, or patients currently on prophylaxis

You may not qualify if…

• Known history of factor IX inhibitors based on existing medical records, laboratory report reviews and patient and legally acceptable representative (LAR) interviews
• HIV (Human immunodeficiency virus) positive, with a viral load equal to or above 400,000 copies/mL and/or CD4+ lymphocyte count equal to or below 200/microL
• Congenital or acquired coagulation disorders other than haemophilia B
• Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
• Immune modulating or chemotherapeutic medication

Where it is running

• Novo Nordisk Investigational Site — Los Angeles, California, United States
• Novo Nordisk Investigational Site — Jacksonville, Florida, United States
• Novo Nordisk Investigational Site — Augusta, Georgia, United States
• Novo Nordisk Investigational Site — Iowa City, Iowa, United States
• Novo Nordisk Investigational Site — Baltimore, Maryland, United States
• Novo Nordisk Investigational Site — Minneapolis, Minnesota, United States
• Novo Nordisk Investigational Site — Omaha, Nebraska, United States
• Novo Nordisk Investigational Site — Newark, New Jersey, United States
• Novo Nordisk Investigational Site — New York, New York, United States
• Novo Nordisk Investigational Site — Syracuse, New York, United States
• Novo Nordisk Investigational Site — Hershey, Pennsylvania, United States
• Novo Nordisk Investigational Site — Houston, Texas, United States
• Novo Nordisk Investigational Site — Edmonton, Alberta, Canada
• Novo Nordisk Investigational Site — Le Kremlin-Bicêtre, France
• Novo Nordisk Investigational Site — Lyon, France
• Novo Nordisk Investigational Site — Bonn, Germany
• Novo Nordisk Investigational Site — Duisburg, Germany
• Novo Nordisk Investigational Site — Giessen, Germany
• Novo Nordisk Investigational Site — Hanover, Germany
• Novo Nordisk Investigational Site — Budapest, Hungary
• Novo Nordisk Investigational Site — Florence, Italy
• Novo Nordisk Investigational Site — Milan, Italy
• Novo Nordisk Investigational Site — Kawasaki-shi, Kanagawa, Japan
• Novo Nordisk Investigational Site — Nagoya-shi, Aichi, Japan
• Novo Nordisk Investigational Site — Nishinomiya-shi, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.